PA
INFI

Pinnacle Associates’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Pinnacle Associates’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-11,524
Closed -$15K – 692
2017
Q3 		$15K Sell
11,524
-1,235,435
-99% -$1.53M ﹤0.01% 667
2017
Q2 		$1.96M Sell
1,246,959
-59,720
-5% -$115K 0.04% 306
2017
Q1 		$4.22M Sell
1,306,679
-30,142
-2% -$74.2K 0.08% 224
2016
Q4 		$1.8M Sell
1,336,821
-24,001
-2% -$31.3K 0.04% 315
2016
Q3 		$2.12M Sell
1,360,822
-102,220
-7% -$157K 0.04% 297
2016
Q2 		$1.95M Sell
1,463,042
-8,069
-0.5% -$37.7K 0.04% 298
2016
Q1 		$7.75M Buy
1,471,111
+17,130
+1% +$105K 0.17% 144
2015
Q4 		$11.4M Buy
1,453,981
+108,051
+8% +$930K 0.24% 110
2015
Q3 		$11.4M Buy
+1,345,930
New +$12.4M 0.25% 100

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Pinnacle Associates's INFI Position: Q4 2017 in Review

Pinnacle Associates sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q4 2017, closing a stake of 11,524 shares — an estimated $15K sold.

Pinnacle Associates first reported a position in INFI in Q3 2015 and held it in 9 quarters. The position peaked at $11.4M in Q4 2015. 65 funds tracked by Wall St. Rank hold INFI as of Q4 2017.

  • Pinnacle Associates reported no remaining Infinity Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Pinnacle Associates sold 11,524 Infinity Pharmaceuticals, Inc. shares in Q4 2017, an estimated $15K.
  • Pinnacle Associates first reported a position in Infinity Pharmaceuticals, Inc. in Q3 2015 and held it in 9 quarters.
  • Pinnacle Associates's Infinity Pharmaceuticals, Inc. position peaked at $11.4M in Q4 2015.
  • 65 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q4 2017.

Based on Pinnacle Associates's 13F filing for Q4 2017, filed 12 Feb 2018.